ANP.AX - Antisense Therapeutics Limited

ASX - ASX Delayed price. Currency in AUD
Currency in AUD

Valuation measures4

Market cap (intra-day) 61.58M
Enterprise value 45.14M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)3.84
Enterprise value/revenue N/A
Enterprise value/EBITDA -4.60

Trading information

Stock price history

Beta (5Y monthly) 0.58
52-week change 3-42.86%
S&P500 52-week change 31.77%
52-week high 30.1500
52-week low 30.0600
50-day moving average 30.0796
200-day moving average 30.0893

Share statistics

Avg vol (3-month) 3432.75k
Avg vol (10-day) 3483k
Shares outstanding 5669.32M
Implied shares outstanding 6N/A
Float 8532.59M
% held by insiders 120.28%
% held by institutions 14.94%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 306 Nov 2013

Financial highlights

Fiscal year

Fiscal year ends 30 June 2022
Most-recent quarter (mrq)31 Dec 2022


Profit margin 0.00%
Operating margin (ttm)-404.02%

Management effectiveness

Return on assets (ttm)-23.52%
Return on equity (ttm)-40.56%

Income statement

Revenue (ttm)2.01M
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)89.50%
Gross profit (ttm)1.71M
Net income avi to common (ttm)-8.1M
Diluted EPS (ttm)-0.0100
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)16.62M
Total cash per share (mrq)0.03
Total debt (mrq)185.37k
Total debt/equity (mrq)1.15
Current ratio (mrq)9.00
Book value per share (mrq)0.02

Cash flow statement

Operating cash flow (ttm)-6.77M
Levered free cash flow (ttm)-3.78M